Company intelligence / Profile preview

Cumulative Therapeutics

Houston, Texas, USA

Ownership: Private
Development stage: Other

Overview

Cumulative Therapeutics is a pre-clinical stage biotechnology company focused on developing novel small molecule therapies for oncology indications. The company specializes in targeting the RAS signaling pathway, specifically by disrupting protein-protein interactions that are traditionally considered undruggable. Their lead research focuses on the Grb2-SOS1 complex to inhibit downstream RAS activation in various cancers. By utilizing a proprietary discovery approach, Cumulative Therapeutics aims to address resistance in RAS-driven tumors and provide new therapeutic options for patients with solid and hematologic malignancies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

University of Texas MD Anderson Cancer CenterFannin Innovation Studio

Beyond the preview

Go deeper on Cumulative Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cumulative Therapeutics.

Explore the full profile